Search
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. … In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries
Fexinidazole
go.drugbank.com/drugs/DB12265ApprovedTransmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively … [A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940]
Categories: MATE 2-K InhibitorsPeginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigational[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Categories: Interferon Type I, Compounds used in a research, industrial, or household settingOxitriptan
go.drugbank.com/drugs/DB02959ApprovedInvestigationalNutraceuticalWithdrawnthe United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication … More study is needed to determine efficacy in treating depression.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigationalLopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's
Categories: Antivirals used in combination for the treatment of HIV infectionsRescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Crotalus adamanteus antivenin
go.drugbank.com/drugs/DB13893ApprovedEach year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. … It is intravenously administered to limit systemic toxicity [FDA label].
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedIn addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.
Categories: Vitamin K AntagonistsVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigational[L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.